Company news

Dare Bioscience, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

June 12, 2025

Daré Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Daré’s DARE to PLAY Sildenafil Cream

June 4, 2025

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

May 13, 2025

Daré Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025

May 6, 2025

Daré Bioscience to Present at the Fierce Pharma Engage Summit on Breaking Barriers and Building Access: Communicating Bold Moves in Women’s Health Innovation

April 23, 2025

Daré Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year

April 7, 2025

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

March 31, 2025

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

March 24, 2025

Daré Bioscience and Theramex Announce Co-Development and Licensing Agreement for a Potential Biodegradable Long-Acting Contraceptive Implant

February 20, 2025

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

February 5, 2025

Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)

December 15, 2024

Daré Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

December 9, 2024

Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

December 3, 2024

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

November 13, 2024

Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites

November 12, 2024

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

November 6, 2024

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health

October 22, 2024

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

October 20, 2024

Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

August 25, 2024

Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

August 12, 2024

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

August 11, 2024

Daré Bioscience to Host Second Quarter 2024 Financial Results and Company Update Conference Call and Webcast on August 12, 2024

August 4, 2024

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

July 18, 2024

Daré Bioscience Announces Reverse Stock Split

June 26, 2024

Daré Bioscience Announces Publication in Obstetrics & Gynecology of Phase 2b Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder

June 23, 2024

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

May 13, 2024

Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024

May 6, 2024

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

May 1, 2024

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts

April 29, 2024

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

April 22, 2024

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

April 10, 2024

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

March 27, 2024

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

January 30, 2024

Daré Bioscience Announces Executive Team and Board of Directors Changes

January 25, 2024

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

January 16, 2024

Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases

January 3, 2024

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

December 25, 2023

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

December 19, 2023

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study

December 12, 2023

Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy Associated with Menopause

December 6, 2023

Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive

December 3, 2023

Daré Bioscience and Premier Research Extend Strategic Partnership to Accelerate the Clinical Development of Daré’s Novel Women’s Health Programs

November 19, 2023

Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update

November 8, 2023

Daré Bioscience to Host Third Quarter 2023 Financial Results and Company Update Conference Call and Webcast on November 9, 2023

November 1, 2023

Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program

October 31, 2023

Daré Bioscience Announces Achievement of First Commercial Milestone Under License Agreement for XACIATO™ (Clindamycin Phosphate) Vaginal Gel, 2%, FDA-Approved Treatment for Bacterial Vaginosis in Females 12 Years or Older

October 15, 2023

Daré Bioscience Completes Previously Announced Equity Financing

September 4, 2023

Daré Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

August 29, 2023

Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update

August 9, 2023

Daré Bioscience Announces Publication in The Journal of The North American Menopause Society of Positive Efficacy Findings for the Treatment of Menopausal Symptoms from a Phase 1/2 Clinical Trial of DARE-HRT1 Intravaginal Rings

August 8, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 20 calls. Every call is listed under its year.

Decks

The 5 newest of 55 decks. Every deck is listed under its year.